Magnesium sulphate in the prevention of Post-ERCP Pancreatitis: a prospective randomised, placebo-controlled multicentre study

niversity Hospital Greifswald (Germany)0 个研究点目标入组 502 人开始时间: 2009年4月7日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Adult (greater than or equal to 18 years of age) patients (male and female) with a medical indication for a diagnostic or therapeutic endoscopic retrograde cholangiopancreatography (ERCP)
•2. Written informed consent

•1. Known allergy or intolerance to one of the medicaments utilised in the study or their ingredients
•2. Participation in another clinical study during the previous four weeks
•3. Pregnancy or breast feeding
•4. Acute pancreatitis
•5. Renal insufficiency greater than or equal to stadium 4 (National Kidney Foundation Disease Outcomes Quality Initiative™ [NKF KDOQI™])
•6. Hyperthyroidism
•7. Symptomatic bradycardia less than 35 bpm
•8. Atrioventricular block greater than 1° or other cardial conduction defects
•9. Myasthenia gravis
•10. Liver cirrhosis Child C
•11. Any apparent coagulopathy
•12. Kidney stone diathesis (calcium-magnesium-ammonium-phosphate stones)
•13. Mental impairment, addictive or other disorders leading to the patients inability to understand the scope and possible consequences of a participation in the clinical trial
•14. Magnesium medication within 14 days before the procedure
•15. Inability to give informed consent

发起方

niversity Hospital Greifswald (Germany)